TY - JOUR
T1 - Urinary bladder tumor markers
AU - Lokeshwar, Vinata B.
AU - Selzer, Marie G.
N1 - Funding Information:
This work was supported by NCI/NIH R01 CA-72821-06A2.
PY - 2006/11
Y1 - 2006/11
N2 - Bladder cancer is amenable to biomarker development because many tumor-associated molecules are secreted in urine. Tumor cells are shed in urine, and, therefore, tests that detect tumor cell-surface markers have also been developed to diagnose bladder cancer and monitor its recurrence. Several bladder tumor markers show higher sensitivity than cytology, but most have lower specificity. In addition to markers that use conventional technologies such as enzyme-linked immunosorbent assay, point-of-care devices, reverse transcriptase polymerase chain reaction, fluorescent in situ hybridization, and immunocytochemistry, proteomic and gene profiling approaches are being used to find new biomarkers to assist in the molecular profiling of bladder cancer. This review describes both new and well-studied bladder tumor markers.
AB - Bladder cancer is amenable to biomarker development because many tumor-associated molecules are secreted in urine. Tumor cells are shed in urine, and, therefore, tests that detect tumor cell-surface markers have also been developed to diagnose bladder cancer and monitor its recurrence. Several bladder tumor markers show higher sensitivity than cytology, but most have lower specificity. In addition to markers that use conventional technologies such as enzyme-linked immunosorbent assay, point-of-care devices, reverse transcriptase polymerase chain reaction, fluorescent in situ hybridization, and immunocytochemistry, proteomic and gene profiling approaches are being used to find new biomarkers to assist in the molecular profiling of bladder cancer. This review describes both new and well-studied bladder tumor markers.
KW - Bladder cancer
KW - Diagnosis
KW - Surveillance
KW - Tumor markers
UR - http://www.scopus.com/inward/record.url?scp=33751318494&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33751318494&partnerID=8YFLogxK
U2 - 10.1016/j.urolonc.2006.07.003
DO - 10.1016/j.urolonc.2006.07.003
M3 - Review article
C2 - 17138134
AN - SCOPUS:33751318494
SN - 1078-1439
VL - 24
SP - 528
EP - 537
JO - Urologic Oncology: Seminars and Original Investigations
JF - Urologic Oncology: Seminars and Original Investigations
IS - 6
ER -